COMMUNIQUÉS West-GlobeNewswire

Wayman Place Partners with SafeSpace Global to Enhance Resident Safety with Non-Wearable Elopement Detection
14/11/2025
Knoxville, TN , Nov. 14, 2025 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID:SSGC), a global leader in multimodal AI technology, is pleased to announce a partnership with Wayman Place, a trusted senior living [...]
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
14/11/2025
Received FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding 25 months in ongoing Phase 2 trial Advanced DRP ® platform through new licensing [...]
Trinity Biotech Announces Collaboration to Advance Epigenetic Analysis for EpiCapture Prostate Cancer Test
14/11/2025
DUBLIN, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today [...]
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
14/11/2025
Phase 1 trial evaluating GTB-3650 TriKE ® for relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to actively enroll with the next update anticipated in Q1 2026 GTB-5550 TriKE ® IND [...]
Vaso Corporation Announces Financial Results for Third Quarter of 2025
14/11/2025
PLAINVIEW, N.Y., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional sales [...]
Windtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent Estate
14/11/2025
Windtree has a total of 59 issued or allowed patents and 17 pending patents for Istaroxime and its SERCA2a activators Windtree received recent notification of allowed Istaroxime patents for acute heart failure in Canada [...]
Cantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price Target of $31 Following Strong IM8 Growth
14/11/2025
IM8’s Strong Unit Economics—60% Margins and 3.9-Month Payback—Central to Cantor’s Bullish Outlook Cantor Notes PRE’s ~$120M Liquidity and 387 BTC Treasury as Strengthening the Company’s Financial Position Cantor [...]
Vericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025
14/11/2025
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will [...]
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
14/11/2025
Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at [...]
AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth
14/11/2025
– FDA Type 2a meeting scheduled for November 19, 2025, to review AEON’s analytical development plan and initial data – – Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencing and highly [...]
Sienna Announces November Dividend
14/11/2025
MARKHAM, Ontario, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
14/11/2025
GLEN ALLEN, Va., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and [...]
IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights
14/11/2025
Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, although statistical [...]
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best [...]
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
14/11/2025
NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business [...]
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates
14/11/2025
Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) Demonstrated continued best-in- [...]
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
14/11/2025
WALTHAM, Mass. and BOULDER, Colo., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today [...]
Nanox Partners with French Radiology Group Olympe Imagerie to Advance Clinical Validation in Europe
14/11/2025
Olympe Imagerie to deploy Nanox.ARC at Paris-area Hospital Privé Jacques Cartier MASSY for lung cancer screening applications PETACH TIKVA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “ [...]
Lifeward Ltd. Reports Third Quarter 2025 Financial Results
14/11/2025
Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27% decrease in quarterly Non [...]

Pages